MEDICAL CANNABIS FOR THE GERMAN MARKET
01 _ About the Project
Canify AG (formerly Bavaria Weed GmbH) is one of the first pharmaceutical companies with a manufacturing licence for the unlimited importation, packaging and market release of raw materials of cannabis in the European Union. Due to the in-house production, the company is able to purchase raw materials of cannabis from approved manufacturers in large quantities, to store them almost indefinitely, and package it as an active ingredient and/or medicine and market it in Europe with their own label or as a third-label product. The company distributes its products to European pharmaceutical wholesalers as well as directly to pharmacies.
Since March 2017, the sale of cannabis for medical purposes has been legal in Germany and is subject to the strict regulations of the Cannabis Agency of the Federal Institute for Drugs and Medical Devices, as well as the health authorities of the federal states. Since then, medical cannabis has been available in German pharmacies upon presentation of a prescription. More and more patients are switching from conventional preparations to alternative medicinal cannabis because, unlike conventional painkillers, it is not physically addictive.
The German market offers extremely high growth potential for Canify, as certified production in Germany means that raw materials of cannabis can be imported in correspondingly high quantities, stocked, processed according to demand and thus delivered in real time. Canify will be the first manufacturer to be able to guarantee pharmacies a delivery capability of 24 hours from receipt of order.
-
Company Foundation
March 2018
-
Partner since
June 2018
-
Management
S. Mielcarek, N. Frenzel, A. Wilkens, S. von Pistor, L. Jenssen, S. Affüper
-
Form of Enterprise
AG
-
Locations
Herrsching, Leipheim
-
Industry
Pharma
-
More Information
canify-pharma.de
"The medical cannabis market is not simple, but I am confident that we will master this challenge and Canify will become one of the leading cannabis companies in europe. We are delighted to have the support of the Patentpool Group."
Sascha Mielcarek
CEO Canify AG
02 _ Highlights
What distinguishes Canify
DISTINGUISHING FEATURES OF CANIFY COMPETITIVE BUSINESS CASE
The rapidly growing German market since the legalization of medical cannabis in 2017 and the pioneering role of Canify in this market creates an extremely competitive business case.
PRODUCTION AND TOP-LEVEL SERVICE
As a pharmaceutical company, Canify AG meets the highest standards in the production of high-quality medicinal cannabis flowers and meets the needs of customers with first-class service.
STRATEGIC ORIENTATION
With its own production, the processing of cannabis for third parties and the Canify Clinics, Canify AG is broadly positioned in the cannabis market.
EXPERIENCE & KNOW HOW
Our experienced management team is strongly involved in the Canify project and has been supporting the young company since its foundation.
LEAD INVESTOR
With more than 20 years of experience in management and financing of disruptive technologies, Patentpool is involved as lead investor and provides operational support to the company.
"When we got to know the young company Canify in summer 2018, we knew immediately that this was a unique opportunity with high growth and revenues potential. After the successful market entry, we support Canify AG to become one of the leading cannabis companies in Europe."
Dr. Heiner Pollert
CEO Patentpool Group
